NDC codes

500656 NDC codes with hospital pricing data in the network.

• NDC 65219-0184-20 — Ketamine Inj 10 mg/mL 20 mL (UD) (100 hospitals, 1,011–1,209 samples)
• NDC 00990-7930-03 — DEXTROSE 10 % IV BOLUS (PH NICU/PEDS) (138 hospitals, 1,002–1,209 samples)
• NDC 25021-0244-10 — BORTEZOMIB 3.5 MG IJ SOLR (139 hospitals, 1,101–1,209 samples)
• NDC 63323-0824-75 — D15W INFUSION (30 hospitals, 1,002–1,209 samples)
• NDC 81483-0006-00 — Ketamine Inj 10 mg/mL 5 mL (UD) (34 hospitals, 1,011–1,209 samples)
• NDC 00029-6049-59 — amoxicillin 400 mg/5 mL Oral Liq 5 mL (11 hospitals, 1,127–1,208 samples)
• NDC 00264-5705-10 — Heparin Inj 5,000 units/0.5 mL (UD) (21 hospitals, 1,028–1,208 samples)
• NDC 264315511 — cefTRIAXone in dextrose 2 gram/50 mL Piggyback 1 Each BAG (92 hospitals, 515–1,208 samples)
• NDC 25021082010 — METHYLPREDNISOLONE ACETATE 40 MG/ML SUSPENSION FOR INJECTION (39 hospitals, 596–1,208 samples)
• NDC 781320885 — Ceftriaxone Sodium For Inj 1 GM (77 hospitals, 766–1,207 samples)
• NDC 00048-1040-13 — levothyroxine 50 mcg Tab (13 hospitals, 1,126–1,207 samples)
• NDC 00904-6377-61 — OLANZAPINE 5 MG ORAL TAB (300 hospitals, 1,135–1,207 samples)
• NDC 66993-0730-51 — DEXAMETHASONE 4 MG PO TABS (146 hospitals, 955–1,207 samples)
• NDC 00407-1412-34 — IOHEXOL 240 MG IODINE/ML IV SOLN 150 ML BTL (48 hospitals, 955–1,207 samples)
• NDC 409471342 — LIDOCAINE (PF) 10 MG/ML (1 %) INJECTION SOLUTION (26 hospitals, 919–1,207 samples)
• NDC 60505-6230-04 — PACLITAXEL PROTEIN-BOUND PART 100 MG IV SUSR (120 hospitals, 990–1,206 samples)
• NDC 00071-4259-03 — INJECTION, DIPHENHYDRAMINE HCL, UP TO 50 MG (10 hospitals, 873–1,206 samples)
• NDC 00023392102 — ONABOTULINUMTOXINA 200 UNITS RECON SOLN (139 hospitals, 279–1,206 samples)
• NDC 77333093410 — thiamine mononitrate (vitamin B1) 100 mg tablet (250 hospitals, 962–1,205 samples)
• NDC 77333093810 — CYANOCOBALAMIN TAB 1000 MCG (114 hospitals, 962–1,205 samples)
• NDC 00472-0082-16 — ACYCLOVIR 200 MG/5ML PO SUSP (252 hospitals, 1,096–1,204 samples)
• NDC 00469-9400-00 — UNCLASSIFIED DRUGS (4 hospitals, 988–1,204 samples)
• NDC 0054350049 — LIDOCAINE HCL 2 % MUCOSAL SOLUTION (70 hospitals, 304–1,204 samples)
• NDC 0143932801 — BUPIVACAINE HCL 0.25 % (2.5 MG/ML) INJECTION SOLUTION (21 hospitals, 304–1,204 samples)
• NDC 0143933010 — BUPIVACAINE 0.25 % (2.5 MG/ML) INJECTION SOLUTION (PF OR NON-PF) (SO) (25 hospitals, 304–1,204 samples)
• NDC 0143957701 — LIDOCAINE 10 MG/ML (1 %) INFUSION (ANESTHESIA ONLY) (SO) (37 hospitals, 304–1,204 samples)
• NDC 0143957710 — LIDOCAINE 10 MG/ML (1 %) INFUSION (ANESTHESIA ONLY) (SO) (37 hospitals, 304–1,204 samples)
• NDC 0264180031 — SODIUM CHLORIDE 0.9 % INTRAVENOUS SOLUTION (69 hospitals, 304–1,204 samples)
• NDC 0264180032 — SODIUM CHLORIDE 0.9 % INTRAVENOUS SOLUTION (67 hospitals, 304–1,204 samples)
• NDC 0338004931 — SODIUM CHLORIDE 0.9 % INTRAVENOUS SOLUTION (61 hospitals, 304–1,204 samples)
• NDC 0338004938 — SODIUM CHLORIDE 0.9 % INTRAVENOUS SOLUTION (62 hospitals, 304–1,204 samples)
• NDC 0338004941 — SODIUM CHLORIDE 0.9 % INTRAVENOUS SOLUTION (65 hospitals, 304–1,204 samples)
• NDC 0338004948 — SODIUM CHLORIDE 0.9 % INTRAVENOUS SOLUTION (67 hospitals, 304–1,204 samples)
• NDC 0409115901 — BUPIVACAINE 0.25 % (2.5 MG/ML) INJECTION SOLUTION (PF OR NON-PF) (SO) (48 hospitals, 304–1,204 samples)
• NDC 0409115902 — BUPIVACAINE (PF) 0.25 % (2.5 MG/ML) INJECTION SOLUTION (45 hospitals, 304–1,204 samples)
• NDC 0409115909 — BUPIVACAINE (PF) 0.25 % (2.5 MG/ML) INJECTION SOLUTION (21 hospitals, 304–1,204 samples)
• NDC 0409115918 — BUPIVACAINE 0.25 % (2.5 MG/ML) INJECTION SOLUTION (PF OR NON-PF) (SO) (31 hospitals, 304–1,204 samples)
• NDC 0409115919 — BUPIVACAINE 0.25 % (2.5 MG/ML) INJECTION SOLUTION (PF OR NON-PF) (SO) (26 hospitals, 304–1,204 samples)
• NDC 0409116001 — BUPIVACAINE 0.25 % (2.5 MG/ML) INJECTION SOLUTION (PF OR NON-PF) (SO) (40 hospitals, 304–1,204 samples)
• NDC 0409116018 — BUPIVACAINE 0.25 % (2.5 MG/ML) INJECTION SOLUTION (PF OR NON-PF) (SO) (22 hospitals, 304–1,204 samples)
• NDC 0409132305 — LIDOCAINE (PF) 100 MG/5 ML (2 %) INTRAVENOUS SYRINGE (69 hospitals, 304–1,204 samples)
• NDC 0409132315 — LIDOCAINE (PF) 100 MG/5 ML (2 %) INTRAVENOUS SYRINGE (45 hospitals, 304–1,204 samples)
• NDC 0409155919 — BUPIVACAINE (PF) 0.25 % (2.5 MG/ML) INJECTION SOLUTION (27 hospitals, 304–1,204 samples)
• NDC 0409206605 — LIDOCAINE (PF) 20 MG/ML (2 %) INJECTION SOLUTION (SO) (43 hospitals, 304–1,204 samples)
• NDC 0409427602 — LIDOCAINE 10 MG/ML (1 %) INFUSION (ANESTHESIA ONLY) (SO) (41 hospitals, 304–1,204 samples)
• NDC 0409427617 — LIDOCAINE 10 MG/ML (1 %) INJECTION (SO) (40 hospitals, 304–1,204 samples)
• NDC 0409427717 — LIDOCAINE HCL 20 MG/ML (2 %) INJECTION SOLUTION (41 hospitals, 304–1,204 samples)
• NDC 0409427902 — LIDOCAINE (PF) 10 MG/ML (1 %) INJECTION SOLUTION (44 hospitals, 304–1,204 samples)
• NDC 0409471332 — LIDOCAINE 10 MG/ML (1 %) INJECTION (SO) (38 hospitals, 304–1,204 samples)
• NDC 0409471342 — LIDOCAINE (PF) 10 MG/ML (1 %) INJECTION SOLUTION (22 hospitals, 304–1,204 samples)